Ultragenyx Pharmaceutical (NASDAQ: RARE) recently received a number of ratings updates from brokerages and research firms:

  • 12/5/2017 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by analysts at Raymond James Financial, Inc..
  • 12/5/2017 – Ultragenyx Pharmaceutical was given a new $80.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 12/5/2017 – Ultragenyx Pharmaceutical had its price target raised by analysts at Barclays PLC from $60.00 to $62.00. They now have an “equal weight” rating on the stock.
  • 12/4/2017 – Ultragenyx Pharmaceutical was upgraded by analysts at Jefferies Group LLC from a “hold” rating to a “buy” rating. They now have a $72.00 price target on the stock, up previously from $58.00.
  • 11/16/2017 – Ultragenyx Pharmaceutical was given a new $80.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 11/15/2017 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 11/8/2017 – Ultragenyx Pharmaceutical was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. “
  • 11/5/2017 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $76.00 price target on the stock. They wrote, “RARE’s 3Q report this afternoon was relatively uneventful aside from a few small updates: 1) RARE now has biopsy data from 6 adult patients that are included in the FDA review of burosumab (KRN23); 2) 48 week Phase 3 data for burosumab in adults will be available by YE17; and 3) the DMTX acquisition could close as early as Nov 7 th . Additionally, the company plans on hosting an analyst day in NY on December 4 th during which they plan on sharing some additional details regarding their earlier stage pipeline.””
  • 11/3/2017 – Ultragenyx Pharmaceutical had its price target lowered by analysts at Robert W. Baird from $85.00 to $80.00. They now have an “outperform” rating on the stock.
  • 10/25/2017 – Ultragenyx Pharmaceutical was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. “

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ RARE) traded down $1.80 during mid-day trading on Wednesday, reaching $49.96. 1,220,000 shares of the company traded hands, compared to its average volume of 438,033. Ultragenyx Pharmaceutical Inc. has a 12 month low of $44.02 and a 12 month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.87). The business had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.02 million. The business’s quarterly revenue was up 81.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.64) earnings per share. equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -7.26 EPS for the current year.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Receive News & Ratings for Ultragenyx Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.